The user has been using oral minoxidil and dutasteride for hair loss without success and is considering adding topical 17α-estradiol, Pyrilutamide, Clascoterone, or cetirizine. They have confirmed low serum DHT levels and are exploring additional treatments due to genetic sensitivity to DHT and prostaglandin D2.
The user is using finasteride, HGH, GHK-CU, BPC-157, KPV, biotin/collagen/keratin vitamins, ketoconazole shampoo, and low-dose naltrexone to address hair loss, avoiding minoxidil due to past shedding experiences. Adenosine is discussed as a potential alternative to minoxidil, though it is noted to be expensive and hard to find.
Minoxidil, finasteride, and RU58841 are discussed as treatments for hair loss. The conversation questions the effectiveness and patience required for these treatments.
The user is using 5% topical minoxidil twice daily and 1.25 mg oral finasteride for hair thinning at the temples. They are considering switching to once-daily minoxidil due to scalp flakiness and future time constraints.
New hair loss treatments, including Breezula, VDPHL01, and PP405, are nearing Phase 3 trials, offering hope for effective solutions. Current treatments like finasteride and minoxidil remain effective, but early intervention is crucial.
Follicium XR™ is a topical treatment for hair loss containing RU58841, AHK-Cu, GHK-Cu Peptide, caffeine, D-Biotin, methylene blue, keratin, and spermidine. RU58841 is considered the most effective ingredient, but concerns exist about its stability in water.
The conversation is about the application timeline for tretinoin and minoxidil. It discusses whether to wait 30 minutes to an hour after applying tretinoin before using minoxidil or to apply tretinoin at night and minoxidil in the morning.
Clascoterone is seen as a promising topical treatment for hair loss, similar to finasteride but without side effects, though concerns exist about its long-term effectiveness. Other treatments discussed include topical minoxidil, ketoconazole, microneedling, and oral options like dutasteride and minoxidil.
Clascoterone 5% solution (Breezula) is a promising alternative for androgenetic alopecia, showing continued hair growth with consistent use and no significant side effects. It may be suitable for those who cannot tolerate finasteride or dutasteride, especially when trying to conceive.
The post and conversation are about skepticism towards HairClone's crowdfunding campaign for a hair loss cure, with users expressing doubt and calling it a scam. Specific treatments mentioned include Minoxidil, finasteride, and RU58841.
The conversation is about making a topical solution from clascoterone powder, with references to using a RU58841 mixing guide for guidance. Concerns about product authenticity and bulk purchase requirements are also discussed.
The user experienced anxiety and a rapid heartbeat after restarting finasteride at 0.25-0.3 mg, considering whether to continue or stop. They also use minoxidil but did not have these side effects with minoxidil alone.
Pelage PP405 is a new hair loss treatment in trials, potentially reactivating dormant hair follicles without affecting hormones. Results are expected in February 2025, offering an alternative to minoxidil and finasteride.
Applying hair loss treatments like minoxidil and finasteride, with concerns about side effects and application timing. Some users experience side effects, while others manage without issues, and there's interest in future treatments like pyrilutamide.
The user experienced noticeable hair regrowth after using minoxidil and stemoxydine together, despite initial shedding. They believe stemoxydine helps hair grow back faster, working well with minoxidil.
The user is experiencing sudden hair loss and is considering micro-needling, low-level light therapy, iron supplements, folihair, and Omega 3. They are hesitant to start finasteride, suspecting the hair loss might be due to telogen effluvium from a past COVID-19 infection.
A new treatment, clascoterone 5% solution, shows significant improvement in male hair loss but is considered expensive and only slightly effective by some. It has no side effects and may influence market competition.
A 25-year-old noticed thinning hair at the temples and started using finasteride (1mg/day) for two months, along with keto shampoo twice a week and vitamins like vitamin D, biotin, and zinc. They are seeing some results and are hopeful about regaining lost hair.
The conversation is about using topical melatonin for hair loss and seeking advice on a safe mixing solution or pre-mixed product. Specific treatments mentioned are minoxidil, finasteride, and RU58841.
The conversation discusses the hair loss treatment Breezula by Cassiopea, which had a successful Phase II trial and is expected to start Phase III by the end of the year. Users are curious about the timeline for availability and note that it performs slightly better than finasteride at 6 months, slightly worse at 12 months, with the benefit of having no side effects.
The user is experiencing hair loss, possibly due to androgenic alopecia or telogen effluvium, and is considering treatments like Minoxidil, Finasteride, or RU58841. They also mention potential iron deficiency and sleep deprivation as contributing factors.
Breezula® (Clascoterone) showed promising results in a Phase 2 trial for treating hair loss, being as effective as Propecia with no serious side effects. It might be released between 2021-2022, and a related acne treatment with the same active ingredient could be used in the meantime.
A 21-year-old male experienced significant hair regrowth using minoxidil 5% topical, oral finasteride 1mg, derma stamping, and ketoconazole shampoo over several months. He reported no side effects and remains optimistic about further progress.
The conversation is about a user's hair loss treatment regimen, which includes Dutasteride, oral Minoxidil, topical Dutasteride, Minoxidil sulfate, antioxidants, and various supplements. The user is also using a derma stamp and has paused Tretinoin due to a TCA peel recovery.
The user discusses a galenic hair lotion containing progesterone, estradiol, cyproterone, hydrocortisone butyrate, and cetirizine pheniramine, which has effectively stopped their hair loss over two years. They are curious about the compatibility of finasteride with the lotion's components and note that their trichologist has successfully used minoxidil and finasteride in similar treatments for others.
User started minoxidil, noticed forehead lines and dark circles, and asked for non-invasive skin aging prevention methods. Another user suggested using tretinoin and hyaluronic acid for long-term benefits.
The conversation discusses the application frequency of a 1% Koshine solution for hair loss, with recommendations varying between once or twice daily. It is noted that the 1% solution is more effective than the 0.5% solution.
The user plans to pause finasteride for two months to test its effects on mood and productivity, then switch to Pyrilutamide while monitoring hormone levels. Concerns are raised about potential hair loss and the effectiveness of Pyrilutamide compared to finasteride.